Avimex Overview

  • Year Founded
  • 1952

Year Founded

  • Status
  • Private

  • Employees
  • 122

Employees

Avimex General Information

Description

Developer and manufacturer of animal health drugs and pharmaceuticals intended to promote animal health and food safety and to enhance clients' competitiveness and success. The company engages in research, development, manufacture, and commercialization of vaccines, pharmaceuticals, disinfectants, and anti-mycotoxin binders for animal health, thereby providing poultry, swine, cattle, and aquaculture markets with relevant solutions to the prevention of diseases and improvement of animal health.

Contact Information

Website
www.avimex.com.mx
Ownership Status
Privately Held (no backing)
Financing Status
Corporation
Corporate Office
  • Maíz Number 18, Colonia Granjas Esmeralda
  • Iztapalapa City Hall
  • Mexico City, 09810
  • Mexico
Primary Industry
Other Pharmaceuticals and Biotechnology
Vertical(s)
LOHAS & Wellness, Manufacturing
Corporate Office
  • Maíz Number 18, Colonia Granjas Esmeralda
  • Iztapalapa City Hall
  • Mexico City, 09810
  • Mexico

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Avimex Patents

  • 30

    Total Documents Applications and Grants

  • Total Patents Families

  • 12

    Granted

  • 8

    Pending

  • Expiring in next 12 mo

Avimex Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3230865-A1 Recombinant vaccine against covid-19 to produce cellular response in individuals with pre-existing immunity Pending 20-Sep-2021
EP-4404961-A1 Recombinant vaccine against covid-19 to produce cellular response in individuals with pre-existing immunity Pending 20-Sep-2021
AU-2021269903-A1 Recombinant vaccine against covid-19 based on a paramyxovirus viral vector Pending 13-May-2020
CA-3178542-A1 Recombinant vaccine against covid-19 based on a paramyxovirus viral vector Pending 13-May-2020
EP-4151232-A1 Recombinant vaccine against covid-19 based on a paramyxovirus viral vector Pending 13-May-2020 C12N15/86
To view Avimex’s complete patent history, request access »

Avimex Executive Team (1)

Name Title Board Seat
Bernardo Lozano-Dubernard Chief Executive Officer & General Director
To view Avimex’s complete executive team members history, request access »

Avimex Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ready to get started?

Request a free trial

Avimex FAQs

  • When was Avimex founded?

    Avimex was founded in 1952.

  • Who is the CEO of Avimex?

    Bernardo Lozano-Dubernard is the CEO of Avimex.

  • Where is Avimex headquartered?

    Avimex is headquartered in Mexico City, Mexico.

  • What is the size of Avimex?

    Avimex has 122 total employees.

  • What industry is Avimex in?

    Avimex’s primary industry is Other Pharmaceuticals and Biotechnology.

  • Is Avimex a private or public company?

    Avimex is a Private company.

  • What is Avimex’s current revenue?

    The current revenue for Avimex is .

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »